Welcome back to CCPR! We’ve got interviews with Kristin Cadenhead, MD on managing psychotic-like experiences, David Beckmann, MD on psychosis and substance use, and Julie Ann Dopheide, PharmD, on metabolic-sparing antipsychotics, plus a review of selective mutism from board member Mariel Zeccola, APRN, PhD. 

There’s heightened talk about risks of psychotropic medications, especially in kids and teens. CCPR favors nonpharmacologic approaches, but we know that psychotropic medications are effective and often lifesaving, and our goal is to guide thoughtful use. We plan to cover this topic, but for now use this statement to clarify and educate: www.tinyurl.com/b6vdhyxe.

Finally, Danielle Reynolds, MS IV, who’s rotating with me, adds: Delta-8, a cannabinoid compound legal in 30 states, is often seen as safe but causes serious mental health effects, including psychosis, even after one use. Warn your patients. 

As always, let us know your thoughts.

Joshua D. Feder, MD
jfeder@thecarlatreport.com